Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Pre-order your Brochure

8th Annual eyeforpharma Sydney 2018 10 - 11 October, 2018|Sydney, Australia

Your 2017 Speaker Faculty

Loretta Croker

Loretta Croker

General Manager, Commercial Operations, CSL Behring

Read more

Loretta Croker is General Manager CSL Behring Australia and New Zealand responsible for the Commercial Operations in both countries. Loretta joined CSL Behring in November 2013. Prior to this, Loretta spent 12 years at Glaxo Smith Kline (GSK) in Australia and Asia. Loretta has 18 years’ experience in the healthcare industry. Loretta holds a Master of Business Administration and is a Graduate of the Australian Institute of Company Directors.

Deidre MacKechnie

Deidre MacKechnie

CEO, MS Australia

Read more

Deidre is the CEO of MS Australia, the national peak advocacy body for people living with MS in Australia. Deidre commenced with MS Australia in early 2013 in the role of Executive Officer and Company Secretary before her appointment as CEO in 2015. Deidre has had an extensive career in Health, initially training as a nurse which led to clinical education, followed by a move to Human Resources and subsequent roles in senior management. Deidre has post graduate qualifications in Education, Human Resource Management and Governance.

Glenn Montgomery

Glenn Montgomery

Director, Patient Access and Healthcare Systems, Novartis

Read more

Glenn Montgomery has worked within the Australian Pharmaceutical Industry for over 30 years.

He is an experienced business leader having worked with large and small teams in companies such as Wyeth, MSD, Abbott and Merck Serono, across diverse portfolios including Women’s health, IVF, Musculoskeletal, Virology, Endocrinology, Neurology and Cardiovascular.

Glenn joined Novartis in 2013 and has lead the evolution of the Immunology & Dermatology Franchise, culminating in the successful launch of new products in dermatology and rheumatology to complement the existing transplant portfolio.

He now heads up the Novartis Patient Access and Healthcare Systems team which provides patient access and optimizes healthcare systems for the benefit of Australian and New Zealand patients.

Glenn holds a Bachelor of Science (Biological Sciences) from Macquarie University and is a qualified Podiatrist.

Novartis
Simon Fisher

Simon Fisher

Chief Scientific Officer, Novartis

Read more

Simon has nearly 20 years’ experience in the biopharmaceutical industry. After graduating in Medicine at Monash University in Melbourne, Simon completed his MBA.  Since leaving clinical medicine, Simon has held roles in Medical Affairs, Clinical development, Regional Clinical Operations and General Management.  Simon has lead both local and regional teams whilst working in Australia, the US, and China.  Simon is currently the Chief Scientific Officer at Novartis Australia and New Zealand.

Simon McErlane

Simon McErlane

Regional Medical Director, Alexion Pharmaceuticals

Read more

Dr Simon McErlane is a medically qualified pharmaceutical executive with 17 years of broad management experience across General Management, Medical Affairs, Medical Information, Pharmacovigilance and Clinical Research in Europe, Asia and Australia.

As VP & Asian Site Head of Development for Takeda, Dr McErlane was responsible for all development activities in Asia Pacific Region. He led a team of over 50 staff, representing 9 different functions and 10 different nationalities. He also contributed to Takeda’s global policies on questions of biomedical ethics, including patient-centricity, and was responsible for creating the Clinical Science function in Asia.

Prior to this he was Medical Director of Takeda UK, responsible for medical affairs and pharmacovigilance as well as leading a medical team of both office and field based staff. His first role at Takeda was as the European Medical Affairs Manager for their Cardiovascular portfolio. He started his pharmaceutical medicine career with medical affairs and clinical development roles at Schwarz Pharma UK, Allergan Europe and Pfizer Australia.

Currently with Alexion Pharmaceuticals as the Regional Medical Director, Asia & Australia, Dr McErlane leads a team of over 15 staff across 6 countries. He is heavily involved in keeping decisions, both within Alexion and in government negotiations throughout Asia & Australia, focused on patient outcomes.

Before joining industry Dr McErlane trained in Emergency Medicine at Liverpool Hospital Sydney. He received his MB. BS. BSc. from UNSW, his Diploma of Pharmaceutical Medicine from University of Wales in Cardiff and has attended both INSEAD Singapore and the MGSM Sydney for general management and business education.

Penny Shakespeare

Penny Shakespeare

Deputy Secretary for the Health Benefits Group, Department of Health

Read more

Penny Shakespeare, is currently the acting Deputy Secretary of the Health Benefits Group in the Australian Government Department of Health. This includes the Technology Assessment and Access Division (TAAD), Medical Benefits Division (MBD), Provider Benefits Integrity Division (PBID) and the Office of Chemical Safety (OCS).

Since joining the Department of Health in 2006, Penny has held a number of senior leadership positions. Most recently Penny was the First Assistant Secretary of the Technology Assessment and Access Division (PBD), where she led the division through a period of significant change to further build on the division’s capabilities in Health Technology Assessment.

Penny has also previously led the Health Workforce Division as First Assistant Secretary and as head of the Department’s Medical Benefits Branch and Private Health Insurance Branch.

Prior to joining the Department of Health, Penny worked as an industrial relations lawyer in the Department of Employment and Workplace Relations, and in regulatory policy roles, including as head of the ACT Office of Industrial Relations. She was a member of the National Occupational Health and Safety Commission and the Workplace Relations Ministers’ Advisory Council.

Penny has a Bachelor of Laws, a Masters degree in International Law and is admitted as a Barrister and Solicitor.

Alfredo Martinez-Coll

Alfredo Martinez-Coll

General Manager, Stakeholder Engagement, MTP Connect

Read more

Dr Martinez-Coll is a Graduate of the Australian Institute of Company Directors, a Registered Technology Transfer Professional and a member of the AusMedTech (Medical Devices) National Committee of AusBiotech. With a B.S. in Biomedical Engineering from Louisiana Tech University (USA), a PhD and post-doctoral training in biomedical sciences from University of Technology, Sydney, Alfredo brings more than 16 years research experience in the areas of artificial organs, cardiovascular and cerebrovascular physiology, membrane transport, and oxygen transport to tissue.

Alfredo has worked as a business development manager in Technology Transfer/commercialisation for the past 13 years at public hospitals and in academia. His main areas of interest are sustainable funding for science, entrepreneurship and innovation, project management in science and business development. Alfredo is passionate about engaging with researchers and Industry specialists in the Life Sciences arena to translate research discoveries into social impact. Prior to joining MTPConnect, he was Senior Business Development Manager at UNSW Innovations (the technology transfer/commercialisation entity of The University of New South Wales).

Alida Rossi

Alida Rossi

Customer Excellence Director, AbbVie

Read more

Alida has a Bachelor of Science and started her career in research.  Although rewarding, a career in the commercial application of her science background was where she has been able to truly apply her knowledge and skill.  Alida has over 25 years in the pharmaceutical industry with roles ranging from Sales, Marketing, Key Account Management, Business Unit Management and at the Director level.  She is currently the Customer Excellence Director at Abbvie and her role encompasses responsibility for Learning, Development, Business Intelligence, Analytics, Innovation and Capability for ANZ.

Josie Downey

Josie Downey

Director, Oncology Business Unit, MSD

Read more

Josie Downey is a Business Unit Director for Oncology at MSD. She began her career as a research scientist in the biotech sector. She has had over 20 years’ experience in the pharmaceutical industry and has worked for a number of pharmaceutical companies, most recently joining MSD in 2011 where she has held roles across various divisions as Business Unit Manager in Specialty Care, Marketing Manager in Primary Care and Director of Commercial Operations.

Milton Catelin

Milton Catelin

Chief Executive, Medicines Australia

Read more

Milton Catelin is an Australian who is an experienced CEO and Government & Public Affairs Executive with 35 years' experience, including 20 years of direct participation in international energy and environmental negotiations, policy and strategy. His extensive career has included positions of leadership at CEO and Board level.

Milton returns to Australia after 13 years, having completed senior assignments as Chief Executive of International Public Affairs (IPA), a policy and government affairs firm in London, Chief Executive of the World Coal Association (WCA), and Chief of Partnerships & Public Affairs with the United Nations Environment Programme (UNEP) in Geneva.

Before moving to Geneva, Milton had an extensive career in the Australian Public Service. He worked at the forefront of Australian policy on ozone protection and climate change - leading work on a new Australian ozone protection regime and chairing various international ozone bodies and working as a member of a three person public service team negotiating the terms of the Kyoto Protocol on Climate Change. Over his two decades with the public service Milton held positions within the Departments of Prime Minister & Cabinet, Finance, Health and Environment. This extensive career was recognised in 200 l when he received the Australian Public Service Award for "significant and sustained contribution to the achievements of Environment Australia ".

Milton 's expertise has been highly regarded and sought after around the world and has included positions on expert panels and advisory groups such as former UK Prime Minister Tony Blair's Breaking the Deadlock initiative on climate change and as a member of the World Economic Forum (WEF) Global Agenda Council on Decarbonising Energy.

Pre-order your event brochure

Full speaker list • Full conference agenda • Audience breakdown

Elizabeth de Somer

Elizabeth de Somer

Director Policy, Medicines Australia

Read more

More information coming soon...

Deborah Monk

Deborah Monk

Director of Ethics and Compliance, Medicines Australia

Read more

Deborah holds a Bachelor of Pharmacy from the University of Sydney and a Diploma in Hospital Pharmacy. She also holds a Bachelor of Arts from Macquarie University and a Masters in Public Policy from the University of Sydney

Deborah started her working life as a clinical pharmacist in the Pharmacy Department at a major teaching hospital in Sydney.

Deborah is currently the Director of Ethics and Compliance at Medicines Australia.

Medicines Australia promotes the interests of the industry by encouraging a favourable investment environment, working on behalf of its members in an advocacy and consultative capacity with government and non-government organisations in Australia and overseas.

Deborah’s primary responsibility within Medicines Australia is to manage the Ethical Conduct Program.

Ben Hopkins

Ben Hopkins

Commerical Director, Takeda Pharmaceuticals

Read more

A passionate and energetic sales and marketing professional with experience across a broad range of therapeutic areas including oncology, immunology, CNS, cardiovascular, diabetes, osteoporosis and pain, Ben is currently the Commercial Director for Takeda Pharmaceuticals Australia. He leads Sales, Marketing and Commercial Excellence for the organisations Oncology, Gastroenterology and established brands portfolios.

Ben started his pharmaceutical career 20 years ago with MSD as a Medical Representative, taking on roles of increasing responsibility in Sales and Marketing Management for both retail and speciality markets as well as heading up Demand Planning, New Product Planning and Established Brands portfolios. From there Ben enjoyed Marketing and Business Unit Management roles across five different multinational pharmaceutical companies focussing on hospital and speciality markets and biologics, for new products and in-market brands from early phase development and launch through to patent expiry, including hospital generics and biosimilars.

Ben holds an MBA from the Australian Graduate School of Management, and a PhD in Pharmacology from Monash University where he held Medical Research and teaching roles prior to joining the Pharmaceutical industry.

Richard Clement

Richard Clement

Group Digital Communication Manager, Aspen Pharma

Read more

Richard has been working in the Pharma and Life Sciences space since graduating as a Molecular Biologist in the late eighties.  He has worked in sales and sales management, marketing and training until joining Aspen in 2005 to take on the challenge of providing digital tools to support both sales force and customers.  Richard is now Group Digital Manager for Aspen Pharma and with his small global team oversees web, mobile and social media aspects of the larger Aspen business.

Leisl J Guest

Leisl J Guest

Head of HR ANZ, Janssen

Read more

Responsible for the business unit Human Resources function across the Janssen ANZ business. Member of the Janssen Leadership Team (JLT).

  • Leisl is currently Head of HR, Pharmaceuticals, ANZ, reporting to the Head of HR ANZ.
  • Leisl was previously Executive Director, Human Resources ANZ for Janssen from 1 December 2010 – 1 July 2014.
  • Leisl has over 30 years’ experience as an HR Professional, with more than 12 of those years working at Board level, both internationally and locally in both Sydney & Melbourne. Her experience covers a variety of HR disciplines including HR Strategy, Business Partnering, Talent Management, Capability Development, Talent Acquisition & Recruitment, Organisation Development, Employee Development & Engagement, Performance Management, HR Systems & Process Excellence, Employee Retention, Policy Development and Project Management.
  • Her career with Johnson & Johnson spans almost 15 years in business-unit Human Resources within the Janssen and Johnson & Johnson Medical companies, as well as experience working in Talent Development and in a cross sector role in Asia Pacific within the Global Talent Acquisition.
  • Prior to joining Johnson and Johnson, Leisl spent over 15 years working both locally and internationally in the financial services sector in Investment & Retail banking, Insurance and Superannuation. Specific expertise during this time included operating at HR Director level, Leadership of significant teams (up to 60 people), HR Strategy development & implementation, Project Management and Change Management. She also managed a significant Facilities function in Colonial’s UK operation.
  • During her time with Colonial Financial Services, Leisl was a key HR leader, working on significant M&A deals including the outsourcing of the Banks’ full IT capability to a US based organization as well as the sale of Colonial’s UK Life & Pensions business to Credit Suisse in Europe. The UK deal was valued at 330 million pounds. Leisl was asked by Credit Suisse to remain post sale to manage the decoupling of the UK Investment bank from the Life & Pensions company, as well as closing the Life & Pensions operation. This included all HR & people related activities including change management and workforce restructuring.
  • As Head of HR for Australian Financial Services for Colonial’s retail bank, Leisl oversaw the implementation of significant business model changes including the implementation of the Franchise Banking concept, outsourcing of the entire banks’ valuation function and a significant program of Branch closures across ANZ.
  • Leisl was born raised in Sydney and holds qualifications in Human Resources and Financial services along with a Masters of Business Administration (EMBA), from the Australian Graduate School of Management (AGSM). She is a member of the Australian Human Resources Institute. She is also fluent in German and conversational French.

Luke Cornish

Luke Cornish

Senior Government Relations Manager, MSD

Read more

Luke Cornish is the Government Relations Manager in Australia and is responsible for handling all aspects of policy and political engagement. He joined MSD in 2010 after working as a journalist in the US, UK and Australia.

Luke has worked on a number of policy issues including regulatory reform, biosimilars, and intellectual property rights – specifically data exclusivity and gene patenting. He has a particular interest in oncology, hepatitis C and innovative access models for antibiotics.

Carol Ireland

Carol Ireland

CEO & Managing Director, Epilepsy Action Australia

Read more

A senior executive with an extensive background in the NFP human services sector spanning 35 years; holding chief executive and general management roles; responsibility for client services, revenue generation, branding, marketing, research, communications; significant merger and organisation design experience; providing strong leadership; demonstrated strong commitment to human rights; Fellow of the Australian Institute of Management.

Roberto Castro

Roberto Castro

Commercial Operations Manager, iNova Pharma

Read more

Roberto is a passionate, candid and down-to-earth Senior Manager with experience in multiple industries and disciplines. A Computer Engineer and Finance professional with experience in the Pharmaceuticals, IT and Logistics industries in South America, Europe and Australasia. Roberto’s career in pharmaceuticals industry started not long after finishing his MBA and working for the likes of Novartis, Sandoz, J&J and more recently iNova, where he manages the Commercial Operations. In his free time Roberto enjoys early morning sports down his local beach.

Damian Byers

Damian Byers

Director of Human Resources, Mundipharma

Read more

More information coming soon...

Kylie Bromley

Kylie Bromley

Associate Director of Sales & Marketing, Biogen

Read more

Kylie is currently the Associate Director of Sales and Marketing for Rare Diseases at Biogen Australia and New Zealand.   She is an accomplished senior commercial leader with diverse experience in the biopharmaceutical industry across marketing, sales management, market access, and medical affairs.   In her most recent role prior to joining Biogen, Kylie was National Sales Manager – Haematology/Oncology at Amgen Australia, leading a large highly-functioning team to deliver results in highly competitive markets through the promotion of Neulasta®, XGEVA® and Vectibix®.  This role was preceded by her Marketing Manager role in nephology where she had oversight both Aranesp® and Sensipar®.   

Along with extensive commercial experience spanning the entire product lifecycle (pre-launch, launch and mature phase) in a variety of therapeutic areas including haematology/oncology, nephrology, osteoporosis and most recently in rare paediatric neurological disorders.   Kylie also holds a PhD in Pharmacology and a Bachelor degree in Science (Honors) from the University of Melbourne, and a postgraduate certificate in Marketing Management from the Macquarie Graduate School of Management.

She has a passion for science and innovation; with a desire to ensure patients have access to products and services that can support better outcomes.

Pre-order your event brochure

Full speaker list • Full conference agenda • Audience breakdown

Adrian Bootes

Adrian Bootes

Assistant Secretary, Prescription Medicines Authorisation Branch, Therapeutic Goods Administration

Read more

Adrian is Assistant Secretary, TGA in charge of the Prescription Medicines Authorisation Branch. Adrian has had a 25 year career as a health care professional, professional board member, CEO of ARCS and serving in clinical research and regulatory affairs management for major pharma. In addition to running a busy branch and supporting delivery and improvements of current TGA medicine review processes, Adrian is currently involved in the consultation and delivery of the prescription medicines component of the government’s response to the Expert Review into Medicines and Medicines Devices.

Shaun Holmgreen

Shaun Holmgreen

Head - Operational Excellence, UCB

Read more

Dr Shaun Holmgreen is the Head of Operational Excellence at UCB and is responsible for a range of countries throughout the Pacific Rim. After completing his PhD in Oncology at The Walter & Eliza Hall Institute, Shaun has gone on to expand his understanding of how the industry can impact patient’s lives through the completion of A Masters of Medical Science at UNSW and a Masters of Marketing at Monash University. With over 18 years’ experience in the Australian pharmaceutical industry, Shaun has grown his expertise from a broad range of responsibilities including Medical, Marketing, Sales, Regulatory Affairs and Pharmacovigilance.

A scientist at heart, Shaun is passionate about building brands and improving in-field performance within the pharmaceutical industry, with the ultimate goal of helping to improve the health and well-being of the community. He draws upon strong analytical skills in medicine, solid pharmaceutical brand management experience, and proven ability to develop insightful metrics for field-force effectiveness to power innovative approaches to business development within the pharmaceutical industry. As a former member of the Australian Leadership Team at UCB, Shaun had helped contribute to the overall strategic direction and performance of the successful local UCB affiliate.

Jessica Danaher

Jessica Danaher Galderma

Brand Manager - Prescription, Galderma

Read more

More information coming soon...

Dr Munro Neville

Dr. Munro Neville

Chief Medical Officer, Sonic Clinical Services

Read more

Dr Neville specialises in the design and execution of disease management programs, interventional clinical trials and observational research studies in the primary care settings.  At Pretium, a disease management and research firm he cofounded in 2003, he developed algorithms for the accurate identification from electronic health records of eligible patients for recruitment to programs and studies.  He adapted this approach for use in Sonic Clinical Service’s disease management programs, the WellNet suite of clinical and behavioural interventions.  Munro designed these stepped care programs for patients who have complex needs, multimorbidity or chronic diseases, as well as those who are at higher risk of developing a chronic disease. 

Munro has held a senior appointment with the Mayne Group, then an operator of a large chain of private and public hospitals in Australia and Indonesia, radiology and pathology services and GP practices. At Mayne he developed the group’s ability to undertake detailed clinical costing activities, changed the hospital contracting model to casemix funding (facilitated by the clinical costing knowledge) and introduced the philosophy of evidence based practice.  He also expanded the company’s capacity to undertake health technology assessment to support investment and funding negotiations.

Prior to coming to Australia, he served as Assistant Medical Director for a large private health insurance firm in the UK, AXA PPP healthcare. His work there included analysis of the effects of price signals on health care utilisation, the development of new insurance products and negotiating increased access to cancer centre services for members.

Munro gained his MBBS from St Bartholomew’s Hospital, London, an MBA from the London Business School and an MSc in health care decision analysis from the London School of Economics/London School of Hygiene and Tropical Medicine (joint degree). 

Chris Barakat

Chris Barakat

Director of Business Development, Healthshare

Read more

Chris joined Healthshare in 2013 and leads the company's Business Development efforts. Chris’ key focus areas within Healthshare involve developing viable commercial plans, growing partnerships with key stakeholders and implementing strategies with an elite field force.

Chris comes from a diverse commercial healthcare background. His previous roles include sales in Pfizer's Cardiology, Metabolic and Urology portfolios, Device Technologies in Cardiology, Cardiothoracic Surgery, Respiratory Medicine, ICU, Nuclear Medicine & Orthopaedics and Informa Healthcare with Multinational Pharma, Biotechnology, Venture Capital, Research Institutes and Generic Pharma across Australia and Asia Pacific.

Julia Ballard

Julia Ballard

Senior Journal Publishing Manager, Wiley

Read more

Julia has over 10 years of experience working in the medical publishing industry. She is passionate about ensuring peer-reviewed research reaches the widest possible audience, in ways that will be meaningful, relevant and useful for readers. The current digital transformation happening in publishing offers new ways for authors to enhance the discoverability of their research and to track engagement with content. Julia is excited to share information about these innovations to help you get the most out of your publication strategy.

James Dromey

James Dromey PhD

Chief Operating Officer, Murdoch Childrens Research Institute

Read more

James is Chief Operating Officer at Murdoch Children’s Research Institute (MCRI), one of Australia’s largest research institutes with close to 2000 researchers working across all areas of child and adolescent health.

 

Prior to this he was General Manager – Business Development & Strategy at MCRI, where he led the development and commercialisation of a pipeline of more than 400 research projects on new drugs, devices, diagnostics and digital health technologies.

 

James championed MCRI’s drive into digital health and has positioned the Institute as an international leader in this area. He led the development and implementation of a new model in medical research that facilitates greater collaboration and knowledge transfer across health and technology, engineering and ICT sectors.

 

James has over 17 years’ experience in health and medical research, both as a research scientist and in technology innovation and commercialisation. Previously, James was Business Development Manager at the Walter & Eliza Hall Institute in Melbourne, where he led a number of strategic collaborations with industry partners ranging from SMEs, to top 5 international pharmaceutical and Fortune 500 companies. As a research scientist he was part of a team that developed a first-in-class vaccine for celiac disease that went on to raise over $35 million and is now in clinical trials. His work has resulted in the filing of three patent applications, two of which have been commercialised. James is currently a Non-Executive Director of GI Therapies, an unlisted spin-out from MCRI.

Trent Agnew

Trent Agnew

Client Services Director, Williams Lea Tag

Read more

Trent Agnew is Client Services Director at Williams Lea Tag and manages the creative process across all disciplines, with a strong focus on digital transformation. Trent has successfully created and implemented digital change agendas, creating greater innovation and efficiency for clients across multiple sectors. Winner of Williams Lea Tag’s Global CEO Award for Investment of Choice, Trent has a wealth of experience in designing digital products and services that solve business needs, while ensuring the client’s digital ambition aligns with their strategic goals. Trent is a seasoned public speaker, having been the Keynote speaker for adobe conferences in Australia.

Amit Backliwal

Amit Backliwal

Vice President - Technology and Consulting Services, APAC, QuintilesIMS

Read more

More information coming soon...

Lisa Maguire

Lisa Maguire

Director Corporate Communications & Patient Relations ANZ, Abbvie

Read more

Lisa has over 20 years’ experience in Corporate Communications in a broad range of industry sectors including pharmaceuticals, FMCG, innovation, agriculture, emergency services and media (both television and radio).  Lisa’s is currently the Director of Communications at AbbVie, a global research-driven biopharmaceutical company. Lisa has a degree in Agricultural Science and a Master’s Degree in Communications.

Lisa has a wide skill set across all facets of communications, including traditional media, social media; stakeholders, government and employee relations. She also has extensive experience in building overall company brand equity through broad reaching consumer campaigns to impact public opinion and policy for large scale change.

Wai Kwok

Wai Kwok

Managing Partner, Orchard

Read more

Wai Kwok is Managing Partner at Orchard, one of the leading creative health and wellness agencies in Australia. Wai comes from a strong digital background having worked as Marketing Director across a number of the leading digital agencies in London and Asia Pacific. He has over 15 years’ experience in pharmaceutical marketing. He holds a Masters of Science.in strategic marketing and has published digital best practice guidelines for IBM and ISBA in the UK.

Nick Cimarusti

Nick Cimarusti

CRM Business Unit Manager, Boehringer Ingelheim ANZ

Read more

Nick Cimarusti is CRM Business Unit Manager for Boehringer Ingelheim ANZ where he looks after the implementation of CRM and digital strategies, business analysis and reporting, customer analysis and segmentation, and data science.  He has over 20 years’ experience working in and servicing the pharmaceutical industry and has a keen interest in identifying customer needs to provide innovative solutions.

Pre-order your event brochure

Full speaker list • Full conference agenda • Audience breakdown

Fiona Sheppard

Fiona Sheppard

Sales, Learning & Development Manager ANZ, Johnson & Johnson

Read more

After entering the workforce initially as a registered Nurse, Fiona has spent the past 20 years working within the healthcare industry across both medical devices and pharmaceutical products. Working within sales and marketing roles across a variety of specialty areas including orthopaedics, plastic surgery and cardiac she gradually built her understanding of the different aspects within each specialty. Fiona has recently returned to the medical side of the J&J business after spending the past 7 years at Janssen and this has given her a perfect platform to reflect on how she can bring ‘the best of both worlds’ to create a ‘Best in Class’ offering in her current role as the Sales Learning and Development Manager for the Ethicon business across Australia and New Zealand.

Her previous responsibilities as a project manager included the development and implementation of innovative programs and solutions that offered a value to both patients and healthcare providers. Building these programs was an iterative process and involved a high level of stakeholder engagement to ensure that the programs were aligned to the customer needs and added value beyond a product offering.

Fiona’s areas of expertise lie within managing KOL and customer relationships, prioritising customer value alignment, project management, training program development and facilitation, sales operations and analysis. She holds a diploma of Applied Science in nursing and post graduate studies through the University of Technology in Business Management.

Her passion outside of work is photography, and she can often be found catching a sunrise on the weekend at her local Bronte Beach

Phil Kearney

Phil Kearney

Director – Licensing & External Research, MSD

Read more

Dr Phil Kearney joined Merck Sharp & Dohme Australia in 2007 as the key scout for innovative research and development in the Asia Pacific region for India, South East Asia, Australia, & New Zealand. The Sydney-born scientist has the challenge of uncovering and commercialising discoveries by local researchers that have strong potential to benefit the health of people around the globe.

Dr Kearney is responsible for identifying partnership opportunities with research institutes and biotechnology companies to secure high-value intellectual property for the Merck & Co pipeline. As head of the External Licensing group at the company’s head office in Sydney, Dr Kearney regularly liaises with Australian and New Zealand biotechnology companies and research institutes to look for new chemical and biological entities with therapeutic potential, validated drug targets and new platform technologies.

Dr Kearney holds an MBA from the University of Sydney and completed his PhD in the genetics of the methanol fermenter Methylophilus methylotrophus AS1 at the University of Monash. He went to London to work in the laboratory that was mapping the human Y chromosome and later worked on mapping the X chromosome at the Murdoch Institute in Melbourne.

Dr Kearney then joined the team at St Vincent’s Hospital for more than a decade as the Head of the Haemotology Research Laboratory, where the theme was antisense and ribozyme modification of oncogene expression. He then to moved to Sweden in 2000 to take up the role of Project Leader of Oncology for Active Biotech, a position he held for five years. He left his last post in Scandinavia as Director of Biology and External Research at Danish biotechnology company Santaris Pharma to join the Merck Sharp & Dohme team.

Dr Kearney’s extensive background in oncology and haematology is in keeping with one of Merck Sharp & Dohme’s key focuses as the company looks to secure novel drug targets for cancer treatment and a range of other diseases. As an ambassador for regional science, he places a strong emphasis on his role in convincing international decision-makers within Merck of the worth of investing in Asia-Pacific health and medical research, especially Australian and New Zealand discoveries.

Anza Asahara

Anza Asahara

Project Director
eyeforpharma

Phone: +44 207 422 4312

Email: anza@eyeforpharma.com

Pre-order the detailed event brochure

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown